A new melanoma antigen fatty acid-binding protein 7, involved in proliferation and invasion, is a potential target for immunotherapy and molecular target therapy

Yasufumi Goto, Yuriko Matsuzaki, Sachiko Kurihara, Ayako Shimizu, Tsutomu Okada, Kazuhiko Yamamoto, Hiroshi Murata, Minoru Takata, Hiroyuki Aburatani, Dave S B Hoon, Toshiaki Saida, Yutaka Kawakami

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

The identification of molecules that are preferentially expressed in melanoma cells and involved in their malignant phenotypes is important for understanding melanoma biology and the development of new diagnostic and therapeutic methods. By comparing the expression profile of a melanoma cell line with those of various normal tissues using GeneChip and by confirming the actual expression of the selected genes by reverse transcription-PCR and Northern and Western blot analyses, fatty acid-binding protein 7 (FABP7), which is frequently expressed in melanomas, was identified. Immunohistochemical examination revealed that FABP7 was expressed in 11 of 15 melanoma tissues. By down-regulating the FABP7 expression with FABP7-specific small interfering RNAs, in vitro cell proliferation and Matrigel invasion were suppressed in two of six melanoma cell lines. Overexpression of FABP7 in a FABP7-negative embryonic kidney cell line 293T by transfecting with the FABP7 cDNA resulted in enhanced cell proliferation and Matrigel invasion, indicating that FABP7 plays a role in the malignant phenotype of some melanoma cell lines. IgG antibodies specific for the phage or bacterial recombinant FABP7 protein were detected in 14 of 25 (56%) or in 8 of 31 (26%) sera from melanoma patients, respectively, but not in sera from healthy individuals, indicating that FABP7 is an immunogenic antigen in melanoma patients. These results showed that FABP7 is frequently expressed in melanoma, may be involved in cell proliferation and invasion, and may be a potential target for development of diagnostic and therapeutic methods.

Original languageEnglish
Pages (from-to)4443-4449
Number of pages7
JournalCancer Research
Volume66
Issue number8
DOIs
Publication statusPublished - 2006 Apr 15

Fingerprint

Melanoma-Specific Antigens
Immunotherapy
Melanoma
Therapeutics
Cell Line
Cell Proliferation
Fatty Acid-Binding Protein 7
Phenotype
Serum
Recombinant Proteins
Northern Blotting
Bacteriophages
Small Interfering RNA
Reverse Transcription
Complementary DNA
Immunoglobulin G
Western Blotting

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A new melanoma antigen fatty acid-binding protein 7, involved in proliferation and invasion, is a potential target for immunotherapy and molecular target therapy. / Goto, Yasufumi; Matsuzaki, Yuriko; Kurihara, Sachiko; Shimizu, Ayako; Okada, Tsutomu; Yamamoto, Kazuhiko; Murata, Hiroshi; Takata, Minoru; Aburatani, Hiroyuki; Hoon, Dave S B; Saida, Toshiaki; Kawakami, Yutaka.

In: Cancer Research, Vol. 66, No. 8, 15.04.2006, p. 4443-4449.

Research output: Contribution to journalArticle

Goto, Y, Matsuzaki, Y, Kurihara, S, Shimizu, A, Okada, T, Yamamoto, K, Murata, H, Takata, M, Aburatani, H, Hoon, DSB, Saida, T & Kawakami, Y 2006, 'A new melanoma antigen fatty acid-binding protein 7, involved in proliferation and invasion, is a potential target for immunotherapy and molecular target therapy', Cancer Research, vol. 66, no. 8, pp. 4443-4449. https://doi.org/10.1158/0008-5472.CAN-05-2505
Goto, Yasufumi ; Matsuzaki, Yuriko ; Kurihara, Sachiko ; Shimizu, Ayako ; Okada, Tsutomu ; Yamamoto, Kazuhiko ; Murata, Hiroshi ; Takata, Minoru ; Aburatani, Hiroyuki ; Hoon, Dave S B ; Saida, Toshiaki ; Kawakami, Yutaka. / A new melanoma antigen fatty acid-binding protein 7, involved in proliferation and invasion, is a potential target for immunotherapy and molecular target therapy. In: Cancer Research. 2006 ; Vol. 66, No. 8. pp. 4443-4449.
@article{7f7d7a89be12452dac7ed3830af4339e,
title = "A new melanoma antigen fatty acid-binding protein 7, involved in proliferation and invasion, is a potential target for immunotherapy and molecular target therapy",
abstract = "The identification of molecules that are preferentially expressed in melanoma cells and involved in their malignant phenotypes is important for understanding melanoma biology and the development of new diagnostic and therapeutic methods. By comparing the expression profile of a melanoma cell line with those of various normal tissues using GeneChip and by confirming the actual expression of the selected genes by reverse transcription-PCR and Northern and Western blot analyses, fatty acid-binding protein 7 (FABP7), which is frequently expressed in melanomas, was identified. Immunohistochemical examination revealed that FABP7 was expressed in 11 of 15 melanoma tissues. By down-regulating the FABP7 expression with FABP7-specific small interfering RNAs, in vitro cell proliferation and Matrigel invasion were suppressed in two of six melanoma cell lines. Overexpression of FABP7 in a FABP7-negative embryonic kidney cell line 293T by transfecting with the FABP7 cDNA resulted in enhanced cell proliferation and Matrigel invasion, indicating that FABP7 plays a role in the malignant phenotype of some melanoma cell lines. IgG antibodies specific for the phage or bacterial recombinant FABP7 protein were detected in 14 of 25 (56{\%}) or in 8 of 31 (26{\%}) sera from melanoma patients, respectively, but not in sera from healthy individuals, indicating that FABP7 is an immunogenic antigen in melanoma patients. These results showed that FABP7 is frequently expressed in melanoma, may be involved in cell proliferation and invasion, and may be a potential target for development of diagnostic and therapeutic methods.",
author = "Yasufumi Goto and Yuriko Matsuzaki and Sachiko Kurihara and Ayako Shimizu and Tsutomu Okada and Kazuhiko Yamamoto and Hiroshi Murata and Minoru Takata and Hiroyuki Aburatani and Hoon, {Dave S B} and Toshiaki Saida and Yutaka Kawakami",
year = "2006",
month = "4",
day = "15",
doi = "10.1158/0008-5472.CAN-05-2505",
language = "English",
volume = "66",
pages = "4443--4449",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - A new melanoma antigen fatty acid-binding protein 7, involved in proliferation and invasion, is a potential target for immunotherapy and molecular target therapy

AU - Goto, Yasufumi

AU - Matsuzaki, Yuriko

AU - Kurihara, Sachiko

AU - Shimizu, Ayako

AU - Okada, Tsutomu

AU - Yamamoto, Kazuhiko

AU - Murata, Hiroshi

AU - Takata, Minoru

AU - Aburatani, Hiroyuki

AU - Hoon, Dave S B

AU - Saida, Toshiaki

AU - Kawakami, Yutaka

PY - 2006/4/15

Y1 - 2006/4/15

N2 - The identification of molecules that are preferentially expressed in melanoma cells and involved in their malignant phenotypes is important for understanding melanoma biology and the development of new diagnostic and therapeutic methods. By comparing the expression profile of a melanoma cell line with those of various normal tissues using GeneChip and by confirming the actual expression of the selected genes by reverse transcription-PCR and Northern and Western blot analyses, fatty acid-binding protein 7 (FABP7), which is frequently expressed in melanomas, was identified. Immunohistochemical examination revealed that FABP7 was expressed in 11 of 15 melanoma tissues. By down-regulating the FABP7 expression with FABP7-specific small interfering RNAs, in vitro cell proliferation and Matrigel invasion were suppressed in two of six melanoma cell lines. Overexpression of FABP7 in a FABP7-negative embryonic kidney cell line 293T by transfecting with the FABP7 cDNA resulted in enhanced cell proliferation and Matrigel invasion, indicating that FABP7 plays a role in the malignant phenotype of some melanoma cell lines. IgG antibodies specific for the phage or bacterial recombinant FABP7 protein were detected in 14 of 25 (56%) or in 8 of 31 (26%) sera from melanoma patients, respectively, but not in sera from healthy individuals, indicating that FABP7 is an immunogenic antigen in melanoma patients. These results showed that FABP7 is frequently expressed in melanoma, may be involved in cell proliferation and invasion, and may be a potential target for development of diagnostic and therapeutic methods.

AB - The identification of molecules that are preferentially expressed in melanoma cells and involved in their malignant phenotypes is important for understanding melanoma biology and the development of new diagnostic and therapeutic methods. By comparing the expression profile of a melanoma cell line with those of various normal tissues using GeneChip and by confirming the actual expression of the selected genes by reverse transcription-PCR and Northern and Western blot analyses, fatty acid-binding protein 7 (FABP7), which is frequently expressed in melanomas, was identified. Immunohistochemical examination revealed that FABP7 was expressed in 11 of 15 melanoma tissues. By down-regulating the FABP7 expression with FABP7-specific small interfering RNAs, in vitro cell proliferation and Matrigel invasion were suppressed in two of six melanoma cell lines. Overexpression of FABP7 in a FABP7-negative embryonic kidney cell line 293T by transfecting with the FABP7 cDNA resulted in enhanced cell proliferation and Matrigel invasion, indicating that FABP7 plays a role in the malignant phenotype of some melanoma cell lines. IgG antibodies specific for the phage or bacterial recombinant FABP7 protein were detected in 14 of 25 (56%) or in 8 of 31 (26%) sera from melanoma patients, respectively, but not in sera from healthy individuals, indicating that FABP7 is an immunogenic antigen in melanoma patients. These results showed that FABP7 is frequently expressed in melanoma, may be involved in cell proliferation and invasion, and may be a potential target for development of diagnostic and therapeutic methods.

UR - http://www.scopus.com/inward/record.url?scp=33646255115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646255115&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-2505

DO - 10.1158/0008-5472.CAN-05-2505

M3 - Article

C2 - 16618771

AN - SCOPUS:33646255115

VL - 66

SP - 4443

EP - 4449

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 8

ER -